Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide effects on cardiovascular risk markers in type 2 diabetes
NCT02380521Phase 4Completed
- Sponsor
- University of Palermo
- Start
- Jan 2015
- Primary completion
- Jul 2016
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of exenatide in type 2 diabetes mellitus (T2DM), sponsored by University of Palermo. Primary endpoint: Carotid-Intima Media Thickness at 8 months. Started Jan 2015; status: completed.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02380521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02380521.